Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 意见
• 07/18/23
0
0
嵌入
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论